Filing summary
Issuer and period: The supplied filing is Miragen Therapeutics, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2019. It is not a Viridian Therapeutics filing; the company name in the request metadata does not match the filing.
Business context and reporting period
Miragen was a clinical-stage biopharmaceutical company developing RNA-targeted therapies. Its clinical-stage candidates were cobomarsen, remlarsen, and MRG-110. The company had no approved products and no product-sales revenue. The financial statements are prepared on a going-concern basis.
Key financial metrics
Amounts are in millions of dollars unless otherwise stated.
| Metric | Three months ended June 30, 2019 | Six months ended June 30, 2019 | Comparison |
|---|---|---|---|
| Revenue | $2.51 | $2.89 | Quarter: $2.18 in 2018; six months: $6.97 in 2018 |
| Research and development expense | $8.60 | $17.35 | Quarter: $8.38 in 2018; six months: $14.79 in 2018 |
| General and administrative expense | $2.86 | $6.21 | Quarter: $2.67 in 2018; six months: $5.66 in 2018 |
| Operating loss | $8.94 | $20.68 | Six months: $13.48 in 2018 |
| Net loss | $8.90 | $20.53 | Quarter: $8.71 in 2018; six months: $13.38 in 2018 |
| Net loss per share, basic and diluted | $0.29 | $0.66 | Six months: $0.47 in 2018 |
At June 30, 2019, cash and cash equivalents were $24.0 million and short-term investments were $19.9 million, totaling $43.9 million in cash, cash equivalents, and short-term investments. Total current assets were $48.1 million; current liabilities were $9.1 million; total liabilities were $15.3 million; and stockholders’ equity was $33.4 million. Debt principal outstanding to Silicon Valley Bank was $9.7 million, with $10.2 million reported as the note’s carrying amount including the accreted final payment fee and debt discount.
For the six months, operating cash outflow was $19.0 million, investing cash inflow was $10.2 million, and financing cash inflow was $0.2 million. Cash and cash equivalents declined by $8.6 million to $24.0 million. The filing does not provide a clear product gross margin; revenue was from collaboration and grant activities, not product sales.
Material changes versus the prior comparable period
- Six-month revenue fell $4.1 million year over year, mainly because a $3.7 million Servier development milestone was recognized in the first half of 2018 and not in 2019. The 2019 period included higher Servier research and development reimbursements.
- Six-month R&D expense rose $2.6 million, principally from increased cobomarsen SOLAR and PRISM trial and manufacturing costs, and higher personnel-related costs; lower technology-license fees partly offset the increase.
- Six-month net loss increased $7.2 million, while operating cash use increased $7.1 million.
- Cash, cash equivalents, and short-term investments declined from $62.5 million at December 31, 2018 to $43.9 million at June 30, 2019. Debt principal declined from $10.0 million to $9.7 million.
Outlook, management commentary, risks, and unusual items
- Liquidity and going concern: Management stated that available resources might not fund operations for the year following issuance of the financial statements without changes to operating plans. The filing says substantial doubt existed about the company’s ability to continue as a going concern. Following a restructuring announced in August 2019, management expected resources to fund operations into the second quarter of 2020; that estimate depends on assumptions and anticipated savings. Additional capital will be required, and financing may not be available on acceptable terms or at all.
- Servier termination notice: On August 5, 2019, Servier notified Miragen that it anticipated terminating the collaboration effective February 1, 2020. Miragen expected to regain global MRG-110 rights and could seek a new partner, but future development depends on capital availability. Specified transition and termination costs were not yet estimable and were not expected to materially affect the financial statements.
- Restructuring: Announced August 7, 2019, the plan reduced approximately 26 positions, prioritized cobomarsen and microRNA-29 mimics including remlarsen, and reduced investment in new discovery research. Estimated restructuring charges were approximately $1.5 million, primarily in the third quarter of 2019.
- Clinical outlook: The company expected to report interim Phase 2 remlarsen data before year-end 2019, MRG-110 Phase 1 data before year-end 2019, and primary endpoint data from the cobomarsen SOLAR trial in the first half of 2021. Management said SOLAR site activation had been delayed, though recruitment at active sites was then approximately on pace with expectations. Potential accelerated approval for cobomarsen was not assured.
- Key risks: Clinical efficacy, safety, enrollment, manufacturing and regulatory uncertainty; dependence on outside financing and collaborators; dilution or restrictive financing terms; and the unproven nature of microRNA therapeutics. The company reported no material legal proceedings and no material off-balance-sheet arrangements.
Most important facts for investors to verify
- Confirm the issuer: this filing is for Miragen Therapeutics, Inc., not Viridian Therapeutics.
- Review the going-concern disclosure and test the assumptions behind the stated runway into Q2 2020, including the expected restructuring savings and future financing needs.
- Track Servier’s anticipated termination, the transition costs, and Miragen’s ability and funding to continue or partner MRG-110.
- Monitor cash burn, debt service, and potential equity issuance or other financing, including related dilution and covenants.
- Verify clinical trial enrollment, safety, data timing, and regulatory progress for cobomarsen, remlarsen, and MRG-110 against the stated expectations.